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4ABSTRACT
Hydroxypyrones comprise several classes of molecules characterised by high synthetic
versatility and interesting pharmaceutical activities. Recently, with the aim to produce
innovative anti-cancer agents, we developed a new class of compounds based on the 3-
hydroxy-2-methyl-4-pyrone unit (maltol). In this study, we analysed a previous selected
molecule referred to as maltonis, in order to assess its anti-proliferative activity both in
vitro and in vivo and to characterize its mechanism of action.
We firstly tested in vitro anti-tumour efficacy on a wide panel of human tumour cell lines
of different origins, subsequently focusing on hematopoietic cancer cell lines that resulted
among the most sensitive to maltonis treatments.
Maltonis exposure led to a dose-dependent reduction in cell survival in the leukaemia cell
models studied. Sublethal concentrations of maltonis induced profound cell cycle
perturbations, particularly affecting G2-M phase, whereas treatments with lethal doses
caused the induction of programmed cell death.
In order to clarify the mechanism of action, we showed by cell-free assays that maltonis is
able to alter the chromatin structure inducing the formation of covalent bonds between
genomic DNA and proteins. In addition, we demonstrated the activation of DNA damage
response as a consequence of maltonis treatments.
Moreover, a microarray-based comparative analysis allowed us to better define the
molecular response triggered by maltonis in HL-60 cells, and to identify a peculiar
distribution of down-regulated genes related to specific genomic features.
Finally, a pilot in vivo experiment on a human AML (HL-60) xenograft murine model
demonstrated the tolerability and efficacy of maltonis that allowed to slightly increase mice
survival time.
5Overall, these results show that maltonis exerts its anti-proliferative activity through the
induction of complex chromatin structural modifications, thus affecting key cellular
processes such as RNA processing and DNA replication.
6ABBREVIATIONS
AML Acute myeloid leukaemia
bp Base pair
DAVID Database for Annotation, Visualization and Integrated Discovery
DDR DNA damage response
DR Down-regulated genes
FA Formaldehyde
G4 G-quadruplex
GI Growth inhibition
GO Gene Ontology
IC50 Half maximal inhibitory concentration
kb Kilobase
NCI National Cancer Institute
PCA Principal Component Analysis
PQS Putative G-quadruplex sequence
RT Room temperature
SD Standard deviation
SDS Sodium dodecyl sulfate
TCA Trichloroacetic acid
TSS Transcription Start Site
UR Up-regulated genes
7INTRODUCTION
8New molecules for potential pharmacological uses are continuously synthesized,
developed, and tested. Anti-neoplastic agents are one of the main targets because, although
great progress has been made in the treatment of neoplastic diseases, the survival of
patients affected by tumour remains in many cases very limited (Tobias and Hochhauser,
2010). In these cases, the main problems are related to the lack of specific therapies as well
as to the resistance to currently used chemotherapeutic drugs, which are furthermore
cytotoxic, thus causing severe side effects. In this light, there is an urgent necessity to
identify and synthesize new molecules showing both a higher effective and/or selective
anti-tumour activity and increased human body tolerability.
Moreover, a detailed comprehension of drug molecular mechanisms could help scientists
to understand the basic science involved and, therefore, to develop new and improved
drugs with fewer side effects.
The aims of our studies were to assess the anti-proliferative effects of maltonis, a maltol
derived compound, both in vitro and in vivo and to characterize its mechanism of action.
In this chapter we will provide fundamental concepts related to cancer, hydroxypyrones,
the family of molecules maltonis belongs to, and chromatin landscape, in order to proper
illustrate Results and Discussion sections.
91. Cancer
Cancer is one of the main causes of morbidity and mortality worldwide, with
approximately 14.1 million new cases and 8.2 million cancer related deaths reported in
2012, thus affecting life expectancy and producing a negative impact on society (Ferlay et
al, 2015). World Health Organization (WHO) estimates that if current cancer rates remain
unchanged the number of new cases is expected to rise by about 75%. This will bring the
number of cancer cases close to 25 million over the next two decades (Stewart and Wild,
2016).
1.1 The hallmarks of cancer
Cancer is a complex progressive multistep disorder that results from the accumulation of
genetic and epigenetic abnormalities, which lead to the transformation of normal cells into
malignant derivatives. Thus, cancer risk increases with age, because more time for the
accumulation of initiating mutations has elapsed and the effects of molecular repair
mechanisms are reduced. Largely, these changes are the result of the interaction between
intrinsic genetic factors and three categories of external agents, including:
 physical carcinogens, such as ultraviolet and ionizing radiation;
 chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxins (food
contaminants) and arsenic (a drinking water contaminant); and
 biological carcinogens, such as infections from certain viruses, bacteria or parasites
(Elliot and Elliot, 2009).
Cancer cells can acquire distinctive and complementary capabilities that enable tumour
growth and metastatic dissemination, providing them with a competitive advantage over
normal cells (Hanahan and Weinberg, 2000):
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- self-sufficiency in growth signals: tumour cells generate many of their own growth
signals, thereby reducing their dependence on stimulation from their normal tissue
microenvironment. This liberation from dependence on exogenously derived signals
disrupts a critically important homeostatic mechanism that normally operates to ensure
a proper behaviour of the various cell types within a tissue.
- insensitivity to growth-inhibitory (anti-growth) signals: cancer cells are also able to
circumvent powerful programs that negatively regulate cell proliferation; many of these
programs depend on the actions of tumour suppressor genes (e.g. RB1).
- evasion of programmed cell death: tumour cells gain the ability to limit or circumvent
apoptosis through a variety of strategies such as the loss of p53 tumour suppressor
function, the increased expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or of
survival signals (Igf1/2) and the down-regulation of pro-apoptotic factors (Bax, Bim).
- limitless replicative potential: tumours acquire the proficiency to maintain telomeric
DNA at lengths sufficient to avoid triggering senescence or apoptosis by up-regulating
expression of telomerase or, less frequently, via an alternative recombination-based
telomere maintenance mechanism.
- sustained angiogenesis: tumours require sustenance in the form of nutrients and oxygen
as well as an ability to evacuate metabolic wastes and carbon dioxide. Tumours appear
to activate the “angiogenic switch” by changing the balance of angiogenesis inducers
(e.g. vascular endothelial growth factor A) and countervailing inhibitors (e.g.
thrombospondin-1).
- tissue invasion and metastasis: the capability for invasion and metastasis enables cancer
cells to escape the primary tumour mass and colonize new terrain in the body. The
multistep process of invasion and metastasis involves several cell-biological traits
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including loss of adherens junctions, expression of matrix-degrading enzymes,
increased motility, and heightened resistance to apoptosis (Figure I).
Figure I. Schematic representation of the six biological capabilities of cancer cells acquired during their
development.
(Adapted from Hanahan and Weinberg, 2011)
Their acquisition is made possible by two enabling characteristics (Figure II). In fact,
underlying these hallmarks are genome instability, which generates the genetic diversity
that expedites their acquisition, and inflammation, which fosters multiple hallmark
functions (Hanahan and Weinberg, 2011).
Yet other distinct attributes of cancer cells have been proposed to be functionally important
(Colotta et al, 2009; Negrini et al, 2010), two such attributes are particularly compelling.
The first involves major reprogramming of cellular energy metabolism in order to support
continuous cell growth and proliferation while the second concerns the active evasion by
cancer cells from attack and elimination by immune cells. Both of these capabilities may
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well prove to facilitate the development and progression of many forms of human cancer
and therefore can be considered to be emerging hallmarks of cancer (Figure II).
Figure II. Schematic representation of emerging hallmarks and enabling characteristics involved in the
pathogenesis of cancers.
(Adapted from Hanahan and Weinberg, 2011)
1.2 Cancer therapy
Due to the multitude of different cancer types, there are several treatment options,
depending upon the location and stage of the cancer and the patient’s general health state.
To date, surgery, radiotherapy and systemic chemotherapy still comprise the standard
treatment in a majority of proliferative disease, showing over many decades to be highly
effective in extending the survival of cancer patients and in eradicating certain types of
tumours with curative outcomes (Weinberg, 2014).
In particular, there are several classes of chemotherapeutics, which can be distinguished by
their structures and mechanisms of action (Haskell, 2001):
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• alkylating agents: impair cell functions by alkylation of DNA, RNA and proteins, thus
inhibiting cell replication. Examples are triazines, nitrogen mustards, alkyl sulfonates
and nitrosoureas.
• metal-based drugs: depending on their structure, there are numerous different
mechanisms of action. An important example is represented by the class of platinum-
containing drugs, which includes cisplatin, carboplatin and oxaliplatin. These platinum
complexes react in the body, binding to DNA and causing DNA strands cross-linking,
which ultimately triggers cell death (Fanelli et al, 2016).
• antimetabolites: compete with or substitute biomolecules involved in DNA and RNA
synthesis thus altering the critical pathways of nucleotide synthesis. Examples are folic
acid, purine and pyrimidine analogues (e.g. 5-fluorouracil).
• topoisomerase inhibitors: topoisomerases are essential enzymes that maintain the
topology and integrity of DNA. Inhibition of topoisomerase interferes with all central
DNA processing steps such as replication, transcription and recombination (e.g.
topotecan and etoposide).
Newer approaches for cancer treatment include anti-tumour antibiotics, hormone
inhibitors, mitosis inhibitors, monoclonal antibodies, signal transduction and enzyme
inhibitors.
The current challenge is to develop novel therapeutic paradigms exploiting the knowledge
derived from molecular, cellular and systems biology studies of tumour formation and
progression (Pavet et al, 2011).
Despite the pleiotropic nature of tumours, several characteristics are shared by almost all
malignancies; therefore a plethora of therapeutic approaches targeting the corresponding
pathways/key players that support or are essential for tumour development are being
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explored and tested (Figure III) (Ferrara et al, 2004; Tennant et al, 2010; Hanahan and
Weinberg, 2011).
Figure III. Therapeutic targeting of the hallmarks of cancer. Illustrative examples of drugs that interfere with
each of the acquired capabilities necessary for tumour growth and progression.
(Adapted from Hanahan and Weinberg, 2011)
Furthermore, abnormal function/recruitment of histone-epigenetic modulators is also
recognized to have a role in tumorigenesis (Feinberg and Tycko, 2004; Esteller, 2008).
Consequently, epigenetic enzymes have been identified as valuable drug targets, as
aberrant DNA methylation and histone modifications can be reverted by the administration
of epigenetic drugs referred to as epi-drugs.
Moreover, although chemotherapy has advanced into the era of targeted drugs, the anti-
tumour efficacies of current therapies are limited, most likely because of the high degree of
cancer clonal heterogeneity, intra-tumour genetic heterogeneity and cell signal complexity.
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As shutdown of a single target does not necessarily eradicate the cancer, the use of
combinations of different drugs has been proposed, and some pioneering research has been
conducted to examine the efficacy of this strategy (Li et al, 2014). Combination therapy
allows for dose reduction at similar efficacy, due to synergistic action and its effect
through different therapeutic targets can minimize the risk of resistance development
(Pavet et al, 2011).
1.3 Haematological malignancies
Among the over 400 types of cancer, a broad group is represented by haematological
neoplasms affecting the blood, bone marrow and lymphoid system.
Hematopoietic malignancies comprise acute and chronic leukaemias, lymphomas,
myeloproliferative disorders, and myelodysplastic syndromes.
The current approach to the classification of haematopoietic and lymphoid malignancies is
based on the integration of morphological, phenotypic, genetic, and clinical features, which
allows the identification of distinct disease entities (Swerdlow et al, 2008).
In particular, leukaemias are defined by an expansion of immature white blood cells in the
bone marrow and blood, where a lack of mature blood cells together with a suppression of
normal residual haematopoiesis eventually leads to anaemia, thrombocytopenia, and
leukopenia, which result in fatigue, bleeding, and infections.
Molecularly, leukaemias represent a heterogeneous disorder characterized by different
rearrangements and dysregulations of genes with important functions in cellular growth,
differentiation, and death (Cline, 1994).
In 2012, there were almost 352000 new cases of leukaemia worldwide, and about 265000
deaths. The disease ranks as the 11th most frequent in terms of cancer incidence and the
10th most common cause of cancer death (Stewart and Wild, 2016).
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Leukaemias can be divided into two main categories, acute and chronic, depending on the
level of maturation of the cells involved and their rates of progression:
- Acute leukaemias are characterized by a rapid increase in the number of immature blood
cells (called blasts). Leukaemia cells multiply quickly and don’t carry out their normal
functions. Acute leukaemias required an aggressive and timely treatment in order to
avoid accumulation of the malignant cells and their spreading to other organs of the
body.
- Chronic leukaemias are characterized by the excessive build-up of relatively mature,
but still abnormal, white blood cells. Typically, chronic leukaemias tend to progress
over a long period of time. Whereas acute leukaemias must be treated immediately,
chronic forms are often monitored for some time before treatment to ensure maximum
effectiveness of therapy.
Additionally, leukaemias are also classified according to the type of bone marrow cell that
is affected:
- Myeloid leukaemias start in immature forms of myeloid cells: white blood cells (other
than lymphocytes), red blood cells, or platelet-making cells (megakaryocytes). They are
also known as myelocytic, myelogenous, or non-lymphocytic leukaemias.
- Lymphocytic leukaemias start in immature forms of lymphocytes. They are also known
as lymphoid or lymphoblastic leukaemias.
By considering whether leukaemias are acute or chronic and whether they are myeloid or
lymphocytic, they can be divided into 4 main types:
 Acute myeloid leukaemia (AML);
 Chronic myeloid leukaemia (CML);
 Acute lymphocytic leukaemia (ALL);
 Chronic lymphocytic leukaemia (CLL).
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In particular, acute myeloid leukaemia, also known as acute myelogenous leukaemia or
acute non-lymphoblastic leukaemia, is a heterogeneous disease characterized by increased
blasts (usually ≥ 20% myeloblasts, monoblasts plus promonocytes, and/or
megakaryoblasts) in blood or bone marrow.
In recent years, there has been improvement in survival, particularly in younger people, but
AML remains a fatal disease for most patients. The WHO classification of AML assigns
patients to categories useful for predicting outcome. Some are classified according to
genetic abnormalities that determine morphological and clinical features (AML with
recurrent genetic abnormalities), others have morphology and/or genetics that relate them
to myelodysplastic syndromes (AML with myelodysplasia-related changes), some are
unique because they follow prior cytotoxic therapy (Therapy-related myeloid neoplasms),
and the remainder are classified by lineage involvement and degree of differentiation
(Arber et al, 2016).
Currently, karyotype and age are the most powerful predictors of prognosis (Burnett, 2012;
Grimwade, 2012). Whole-genome and exome sequencing have revealed a plethora of gene
mutations and submicroscopic genetic defects in this type of leukaemia. Although the
prognostic significance of some alterations, particularly mutated FLT3, NPM1, and
CEBPA, has been recognized, the significance of many others remains to be determined
(Patel et al, 2012). A separate study involving 200 cases reported that AML genomes have
fewer mutations than those of most other adult cancers, with an average of only 13. A total
of 23 genes were significantly mutated, and nearly all samples had at least one non-
synonymous mutation in one of nine categories of genes relevant for pathogenesis,
including transcription factor fusions (18% of cases), the gene encoding nucleophosmin
(NPM1) (27%), tumour suppressor genes (16%), DNA methylation-related genes (44%),
signalling genes (59%), chromatin modifying genes (30%), myeloid transcription factor
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genes (22%), cohesin-complex genes (13%), and spliceosome-complex genes (14%)
(TCGA Research Network, 2013).
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2. The family of hydroxypyrones
Hydroxypyrones comprise several classes of molecules characterised by high synthetic
versatility and high affinity for a range of metal ions, rendering these ligands excellent
choices for the formulation of therapeutic and/or diagnostic metallopharmaceuticals.
Structurally, hydroxypyrones are heterocycles with an hydroxyl group ortho to a ketone,
providing two oxygen donor groups in close proximity (Figure IV) (Santos, 2002).
Figure IV. Chemical structure of 3-hydroxy-4-pyrones.
The main feature of hydroxypyrones is the ability to form exceptionally stable and, in
many cases, neutrally charged complexes with a wide variety of metal ions, including the
trivalent cations Fe3+, Al3+, Ga3+ and In3+, and the divalent ions Zn2+ and Ru2+ and such
metal chelation capacity can be attributed to a substantial charge delocalization within the
six-membered ring (Thompson et al, 2006).
Early applications of hydroxypyrones to medicinal inorganic chemistry generally fall into
one of two main areas: 1) ligand development for potentiation of in situ metal-ion complex
formation and subsequent removal of excess metal ion(s), or 2) metal ion-ligand complex
formation for improving absorption and/or biodistribution characteristics of a particular
metal ion (Thompson and Orvig, 2003).
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2.1 Maltol and its derivatives
Maltol (3-hydroxy-2-methyl-4-pyrone, Figure V), one of the most studied hydroxypyrones,
is a natural compound extensively used, for its flavour and antioxidant properties, as food
additive to impart a desirable malty taste and odour to breads, cakes, beer and other
beverages (Cavalieri, 1947).
Figure V. Chemical structure of maltol, 3-hydroxy-2-methyl-4-pyrone.
Maltol, like related 3-hydroxy-4-pyrones, is an efficient chelator of metal ions such as
Fe3+, Ga3+, Al3+, and VO2+ (Thompson et al, 2006). Ferric maltol is used in the treatment of
anaemia caused by iron deficiency (Gasche et al, 2015; Stallmach and Büning, 2015), and
oxovanadium(IV) complexes of ligands based on maltol were developed as insulin
enhancing agents for treatment of type-2 diabetes mellitus (Saatchi et al, 2005).
Although its high bioavailability and favourable toxicity profiles have been known for a
long time, only recently maltol was found to perform anti-neoplastic activities against
different cancer cellular models. Reactive oxygen species (ROS) generation and the
consequent induction of DNA breaks have been hypothesised as possible mechanisms
responsible for this activity (Hironishi et al, 1996; Yasumoto et al, 2004; Murakami et al,
2006). For this reason, during the last few years, several maltol-derived compounds have
been synthesised and exploited in the formulation of new potential metal-based anti-
tumour drugs (Jakupec and Keppler, 2004; Barve et al, 2009; Kandioller et al, 2009).
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2.2 Maltonis
Recently, with the goal to produce new anticancer agents, the research group of Prof.
Mirco Fanelli in collaboration with that of Prof. Vieri Fusi (Department of Pure and
Applied Sciences, University of Urbino) developed a new class of maltol-derived
molecules coupling maltol and polyamine symmetrically (Fanelli and Fusi, 2010).
The newly designed compounds show two [(3-hydroxy-4-pyron-2-yl)methyl]amine units
separated by different aliphatic spacers with or without a cyclic skeleton (Figure VI).
Figure VI. Chemical structure of maltol-derived compounds formed by two [(3-hydroxy-4-pyron-2-
yl)methyl]amine units separated by different aliphatic spacers with (A) or without (B) a cyclic skeleton.
Malten (N,N’-bis((3-hydroxy-4-pyron-2-yl)methyl)-N,N’-dimethylethylendiamine), the
first selected molecule, showed anti-proliferative activity in eight tumour cell lines derived
from both haematopoietic and solid tumours. Malten exposure led to a dose dependent
reduction in cell survival in all of the neoplastic models analysed, associated with the
activation of programmed cell death and cell cycle arrest (Amatori et al, 2010). In
accordance with biological studies, it was demonstrated that malten treatment modulates
the expression of genes having key roles in cell cycle progression and apoptosis. Complex
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DNA structural modifications are induced by malten, suggesting that a DNA
intermolecular cross-linking activity could be part of the mechanism of action of the
compound (Amatori et al, 2010).
Interestingly, the key of the activity, compared to the previous maltol derivatives reported,
seems to consist in the simultaneous presence of the two amino-spaced maltols.
In light of these results, a new preliminary screening was performed among the maltol-
derived compounds containing a cyclic aliphatic spacer and maltonis (4,10-bis[(3-hydroxy-
4-pyron-2-yl)methyl]-1,7-dimethyl-1,4,7,10-tetraazacyclododecane) was selected.
Maltonis synthetic procedure is easy and low-cost and includes the coupling of maltol,
appropriately protected and activated, with the secondary amine 1,7-dimethyl-1,4,7,10-
tetraazacyclododecane (Figure VII).
Figure VII. Synthetic pathway of maltonis. The procedure includes the coupling of maltol (1), appropriately
protected (2), and activated (3) with the secondary amine 1,7-dimethyl-1,4,7,10-tetraazacyclododecane (4).
TBDMSCl, tert-Butyldimethylsilyl chloride; Im, Imidazole; DMF, N,N-Dimethylformamide; NBS, N-
Bromosuccinimide; AIBN, Azobisisobutyronitrile; CCl4, Carbon tetrachloride; TEA, Triethylamine; THF,
Tetrahydrofuran; EtOH, Ethanol; HClO4, Perchloric acid.
(Adapted from Amatori et al, 2012)
Basicity studies showed that at pH = 7.4, the main species presents in solution for maltonis
is the protonated form HL+, with an internal charge separation (Figure VIII).
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Figure VIII. Location of acidic hydrogen atoms in the protonated HL+ species of maltonis.
(Adapted from Amatori et al, 2012)
In view of its overall positive charge, maltonis HL+ species is likely to interact with the
negatively charged DNA. A preliminary study on this possibility demonstrated that the
HL+ species of maltonis is able to bridge two double-helix fragments through H-bonding
and π-interactions at 27°C in vacuo and water model. A non-covalent approach with the
DNA moiety could be the first step for maltonis to place itself in a favorable position to
allow the formation of covalently bound chromatin structures (Amatori et al, 2012).
Moreover, first attempts to assess anti-proliferative activity of maltonis showed that it
significantly reduces sarcoma cell viability and tumour growth both in vitro and in vivo
(Guerzoni et al, 2014).
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3. Chromatin structure and function
Chromatin is composed by naked DNA wrapped around nucleosomes, organized structures
of specialized proteins called histones, and then packed to form chromosomes (Figure IX).
Figure IX. The organization of DNA within the chromatin structure. The lowest level of organization is the
nucleosome, in which two helical turns of DNA are wound around the outside of a histone octamer.
Nucleosomes are connected to one another by short stretches of linker DNA. At the next level of organization
the string of nucleosomes is folded into a fibre about 30 nm in diameter, and these fibres are then further
folded into higher-order structures.
(Adapted from Felsenfeld and Groudine, 2003)
Chromatin is not a mere depository of the genomic content but rather a signal transduction
platform for extracellular or intracellular signals that regulates all genome functions,
including gene expression, DNA replication and genome stability.
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Upstream signals are translated by chromatin into either transient or long-lasting (and
heritable during cell division) modifications, thereby allowing chromatin to serve the
double function of adapting cells to the environment changes while maintaining their
lineage and/or identity. These modifications forms the epigenome: they are not
modifications of DNA sequences but chemical changes happening on DNA (DNA
methylation) or on specific regions of histone proteins called tails (histone modifications)
that modify chromatin structure in different conformations as more open (euchromatin)
and available to be bound by other proteins, or closed, compacted and then repressed
(heterochromatin) (Felsenfeld and Groudine, 2003).
3.1 DNA methylation
DNA methylation is a post-replication modification occurring mainly at the C5 position of
cytosine (5mC) within CG (or CpG) dinucleotides (Figure X), though it can be also found
in non-CG contexts including CHH and CHG (where H = A, C, or T) as shown in
embryonic stem cells (Lister et al., 2009), oocytes, and preimplantation embryos (Imamura
et al, 2005; Tomizawa et al, 2011).
Figure X. Schematic representation of DNA methylation, which converts cytosine to 5’methyl-cytosine via
the action of DNA methyltransferase (DNMT).
(Adapted from Larkin et al, 2012)
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Overall, mammalian genomes are depleted of CpG sites, likely as a result of mutagenic
potential of 5mC that can deaminate to thymine (Bird, 1980). The remaining CpG sites are
spread out across the genome where they are heavily methylated with the exception of
CpG islands (Bird et al, 1985). CpG islands are stretches of DNA having a CpG density
higher than the rest of the genome (Bird et al, 1985), that map to regions controlling the
expression of most human genes (Saxonov et al, 2006).
DNA methylation is catalysed by DNA methyltransferase enzymes and it is known to act
as a repressor of gene transcription (Kass et al, 1997). DNA methylation regulates gene
silencing by preventing the binding of transcription factors to DNA (Bird and Wolffe,
1999) and by promoting the recruitment of methyl-CpG-binding domain (MBD) proteins
that in turn recruit histone modifying and chromatin-remodelling complexes to methylated
sites (Lopez-Serra and Esteller, 2008).
DNA methylation also plays a key role in genomic imprinting (Kacem and Feil, 2009;
Smith and Meissner, 2013), as well as in the maintenance of pericentric and subtelomeric
heterochromatin (Lehnertz et al, 2003; Gonzalo et al, 2006).
Differently from other modifications, DNA methylation can permanently alter the
expression of genes in cells during cell division and differentiation from embryonic stem
cells into specific tissues. This means that the resulting change is permanent and not
reversible, in order to avoid that a differentiated cell could revert to a stem cell and then
convert in another cell type. However, DNA methylation can be removed either passively,
by dilution as cells divide, or by a faster, active process (Mayer et al, 2000). Active DNA
demethylation can occur in both dividing and non-dividing cells but the process requires
enzymatic reactions and occurs via hydroxylation of the methyl groups that are to be
removed (Ito et al, 2011; He et al, 2011).
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3.2 Histone modifications
Histones are the structural components of the nucleosomes, the basic unit of chromatin
packaging around which the DNA wraps to form chromatin fibres. Histones are very
important proteins involved especially in gene regulation. Five are the major groups of
histones: H1, H2A, H2B, H3 and H4. Histones H2A, H2B, H3 and H4 are known as the
core histones, while H1 is referred to as the linker histone. Two of each of the core
histones are needed to create an octameric nucleosome core and approximately 150 base
pairs of DNA wrap around this core particle, while the linker histone H1 binds the
nucleosome at entry and exit sites of the DNA, blocking it in place (Felsenfeld and
Groudine, 2003). The four core histones are relatively similar in structure and are highly
conserved through evolution, having long tails on the N-terminal end which are more
exposed, protruding from the centre of the nucleosome core. This tail is the location in
which post-translational modifications (PTMs) appear, altering the interaction of histones
with DNA and nuclear proteins (Horn and Peterson, 2002).
An extensive literature documents an elaborate collection of PTMs including acetylation,
phosphorylation, methylation, ubiquitination and ADP-ribosylation that take place on the
tail domains of histones (Figure XI) (Strahl and Allis, 2000).
Figure XI. Snapshot of histone modifications. The histone proteins are decorated by a variety of protein
post-translational modifications critical to dynamic modulation of chromatin structure and function.
(Adapted from Huang et al, 2014)
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These modifications can either function to alter internucleosomal interactions, thereby
affecting the higher order chromatin structure, or act as binding sites for the recruitment of
chromatin-remodelling enzymes.
Histone modifications have a key role in several biological processes such as gene
regulation, DNA repair, chromosome condensation (mitosis) and spermatogenesis
(meiosis). For these reasons, they are often present in specific genomic regions, like
promoters (regions of DNA essential for the transcriptional regulation of genes) and
enhancers (regions of DNA that can be bound by proteins to activate transcription of a
gene).
In particular, histone methylation is an important and widespread type of chromatin
modification that is known to influence biological processes in the context of development
and cellular responses. Histone methylation occurs on all basic residues: arginines, lysines
and histidines. Lysines can be monomethylated (me1), dimethylated (me2) or trimethylated
(me3) on their ε-amine group, arginines can be monomethylated (me1), symmetrically
dimethylated (me2s) or asymmetrically dimethylated (me2a) on their guanidinyl group,
and histidines have been reported to be monomethylated, although this methylation appears
to be rare and has not been further characterized (Greer and Shi, 2012).
Focusing on lysine residues, the most extensively studied histone methylation sites include
histone H3 lysine 4 (H3K4), H3K9, H3K27, H3K36, H3K79 and H4K20.
The trimethylation of different lysine residues of the H3 histone is associated with different
extent of gene transcription. In general, the trimethylation of lysines 4, 36 and 79
(H3K4me3, H3K36me3, H3K79me3) is found predominantly in the euchromatin, while
H3K27me3 and H3K9me3 modifications mark inactive genes or regions and are often
termed heterochromatin modifications (Li et al, 2007).
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3.3 G-quadruplex structures
G-quadruplexes are nucleic acid secondary structures, built upon the motif of the guanine
quartet (Williamson, 1994). Each quartet is composed of four guanines, held together by a
cyclic Hoogsten arrangement of eight hydrogen bonds. The planar G-quartets stack on top
of one another forming four-stranded helical structures. G-quadruplex (G4) formation is
driven by monovalent cations such as Na+ and K+, and hence physiological buffer
conditions favour their formation (Figure XII).
Figure XII. Structure of G-quadruplexes. The building blocks of G-quadruplexes are G-quartets that arise
from the association of four guanines into a cyclic arrangement. The planar G-quartets stack on top of one
another, forming four-stranded helical structures. G-quadruplex formation is driven by monovalent cations
such as Na+ and K+.
(Adapted from Rhodes and Lipps, 2015)
G-quadruplex structures are topologically very polymorphic and can arise from the intra-
or inter-molecular folding of G-rich strands. Intra-molecular folding requires the presence
of four or more G-tracts in one strand, whereas inter-molecular folding can arise from two
or four strands giving rise to parallel or antiparallel structures depending on the orientation
of the strands in a G-quadruplex (Figure XIII) (Burge et al, 2006).
Computational analyses of the human genome searching with the consensus sequence
(G3+N1–7G3+N1–7G3+N1–7G3+) revealed that it contains over 300000 sequences that have the
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potential to form G-quadruplexes referred to as putative G-quadruplex sequences (PQSs)
(Huppert and Balasubramanian, 2005).
Figure XIII. Schematic diagram of the different G-quadruplex folding topologies. G-quadruplex structures
are polymorphic and can be sub-grouped into different families, as for example parallel or antiparallel
according to the orientation of the strands and can be inter- or intra-molecular folded.
(Adapted from Rhodes and Lipps, 2015)
The highest abundance of PQSs is at telomeres, which in humans consist of 5 to 10000
base pairs of the tandemly arranged TTAGGG repeat. They are also highly enriched in
gene promoters, at the border between introns and exons and target immunoglobulin gene
class switch recombination (Maizels and Gray, 2013). Most interestingly, recently it has
emerged that 90% of human DNA replication origins contain PQS motifs, and in higher
densities near origins that are used frequently (Figure XIV) (Besnard et al, 2012).
Figure XIV. G-quadruplexes and the initiation of DNA replication. Origins of replication in humans are GC-
rich and contain PQS. G-quadruplex formation is required for the initiation of DNA replication and the
localization of the G-quadruplex determines the site of initiation.
(Adapted from Rhodes and Lipps, 2015)
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Over the last several years, the increasingly direct evidence for the presence of G-
quadruplexes in vivo, and the identification of proteins that specifically regulate G-
quadruplex folding and unfolding have started to provide insights into G-quadruplex
occurrence and function. In particular, recent data suggest that G-quadruplex formation can
serve both beneficial and regulatory roles in cells such as forming the capping structure of
telomeres, the specification of DNA replication origins in vertebrates, and deleterious
effects as they can impede the progression of replicative DNA polymerases (Rhodes and
Lipps, 2015, Valton et al, 2014).
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AIM OF THE THESIS
Newly designed molecules, belonging to the family of hydroxypyrones, were recently
developed by coupling maltol and polyamine symmetrically.
A preliminary screening among maltol-derived compounds containing a cyclic aliphatic
spacer allowed us to select maltonis (4,10-bis[(3-hydroxy-4-pyron-2-yl)methyl]-1,7-
dimethyl-1,4,7,10-tetraazacyclododecane), for further investigations.
The main purposes of this study were as follows:
- to evaluate the anti-proliferative effect of maltonis and its specificity on a large panel of
human tumour cell lines;
- to characterize maltonis cellular response at both biological and molecular levels;
- to investigate maltonis mechanism of action through both cellular and cell-free assays,
focusing on the modulation of chromatin structure;
- to assess toxicity and therapeutic potential of maltonis by in vivo experiments.
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MATERIALS AND METHODS
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NCI-60 human tumour cell lines screen
The human tumour cell lines of the cancer screening panel were grown in RPMI 1640
medium containing 5% foetal bovine serum (FBS) and 2 mM L-glutamine. Cells were
inoculated into 96 well microtitre plates in 100 µL at plating densities ranging from 5000
to 40000 cells/well depending on the doubling time of individual cell lines. After cell
inoculation, the microtitre plates were incubated at 37°C, 5% CO2, 95% air and 100%
relative humidity for 24 h prior to addition of maltonis. After 24 h, two plates of each cell
line were fixed in situ with trichloroacetic acid (TCA) to represent a measurement of the
cell population for each cell line at the time of drug addition (Tz). Maltonis was solubilized
in dimethyl sulfoxide at 400-fold the final test concentration and stored frozen prior to use.
At the time of drug addition, an aliquot of frozen concentrate was thawed and diluted to
twice the final test concentration with complete medium containing 50 µg/ml gentamicin.
Following maltonis addition at the concentration of 10 µM, the plates were incubated for
an additional 48 h at 37°C, 5% CO2, 95% air, and 100% relative humidity. For adherent
cells, the assay was terminated by the addition of cold TCA. Cells were fixed in situ by the
gentle addition of 50 µl of cold 50% (w/v) TCA (final concentration, 10% TCA) and
incubated for 60 min at 4°C. The supernatant was discarded, and the plates were washed
five times with tap water and air dried. Sulforhodamine B (SRB) solution (100 µl) at 0.4%
(w/v) in 1% acetic acid was added to each well, and plates were incubated for 10 min at
room temperature (RT). After staining, unbound dye was removed by washing five times
with 1% acetic acid and the plates were air dried. Bound stain was subsequently
solubilized with 10 mM trizma base, and the absorbance was read on an automated plate
reader at a wavelength of 515 nm. For suspension cells, the methodology was the same
except that the assay was terminated by fixing settled cells at the bottom of the wells by
gently adding 50 µl of 80% TCA (final concentration, 16% TCA). Using absorbance
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measurements [time zero (Tz), control growth (C), and test growth in the presence of drug
(Ti)], growth percentage was calculated as:
[(Ti-Tz)/(C-Tz)] x 100, Ti ≥ Tz
[(Ti-Tz)/Tz] x 100, Ti < Tz.
Cell cultures, treatments and cell survival evaluation
Immortalized promonocytic leukaemia (U937), acute promyelocytic leukaemia (NB-4),
acute myeloid leukaemia (HL-60) and T-cell leukaemia (JURKAT) human tumour cell
lines were obtained from American Type Culture Collection (ATCC).
Cells were grown in RPMI 1640 (Lonza) supplemented with 10% FBS (Gibco), 1%
penicillin-streptomycin (Sigma-Aldrich) and 1% glutamine (Lonza). All cell lines were
grown in a humidified atmosphere at 37°C as previously described (Fanelli et al, 2008).
Bone marrow derived normal human mesenchymal stem cells (h-MSC) were obtained
from patients with benign bone lesions. After washings, cells were plated in α-MEM
(Lonza), supplemented with 1% penicillin-streptomycin and 20% FBS.
Maltonis was dissolved at 10 mM in double-distilled water as stock solution, stored at
−80°C and subsequently diluted before use. Treatments were carried out at different
concentrations (0.5, 1.0, 2.5 and 5.0 µM) and repeated every 24 h. Cellular viability was
evaluated, after 72 h of treatment, by Trypan blue dye exclusion assay by using TC10
automatic cell counter (Bio-Rad). The 50% inhibitory concentration (IC50) values were
calculated for each cell line with CompuSyn software (ComboSyn, Inc.). The data are
reported as mean ± standard deviation (SD) resulting from three independent experiments.
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Cell cycle analysis and hypodiploid cells estimation
Cell cycle profiles and percentage of hypodiploid cells were studied by propidium iodide
staining procedure as previously reported (Amatori et al, 2009). Cells were fixed in ice-
cold 70% ethanol and stained using a propidium iodide staining solution (50 µg/ml).
Cytofluorimetric acquisitions were carried out with a PAS flow cytometer (Partec) and
sample analysis was carried out with FlowJo 8.6.3 software (Tree Star, Inc.). Cell cycle
percent values were calculated using the Watson pragmatic model and the significance of
changes was evaluated by Student’s t-test.
DNA laddering assay
Following 72 h of treatment with different concentrations of maltonis (2.5 and 5.0 µM),
about 2 × 106 HL-60 cells were harvested, washed once with ice-cold PBS and incubated
in 2 ml of 1X TBS, 0.5% Tween-20 and 1 mM EDTA for 30 min at 4°C. Cells were
centrifuged at 272g (1200 rpm) for 5 min at 4°C and incubated with 0.1% SDS solution for
30 min at RT in a final volume of 0.5 ml. DNA was purified using a QIAquick PCR
purification kit (Qiagen), following the manufacturer’s instructions, separated by 2%
agarose gel electrophoresis (AGE) and detected by ethidium bromide staining.
Native chromatin extraction and DNA preparation
About 2 × 107 HL-60 cells were harvested and the final cell pellet was resuspended in 1 ml
of 1X TBS. An equal volume of 1% Tween/1X TBS (v/v), containing 500 µM
PhenylMethylSulfonyl Fluoride (PMSF), 2 µg/ml Leupeptin and 2 µg/ml Aprotinin, was
added and the sample was incubated in rotation for 1 h at 4°C.
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Cell lysate was homogenised by Dounce pestle on ice and centrifuged at 425g (1500 rpm)
for 3 min at 4°C. Nuclei were separated on 25% sucrose/1X TBS (w/v) underlaid with a
half-volume of 50% sucrose/1X TBS (w/v). After centrifugation at 714g (3000 rpm) for 20
min at 4°C, pelleted nuclei were resuspended in 1 ml of Digestion Buffer (0.32 M sucrose,
50 mM Tris-HCl pH 7.4, 4 mM MgCl2, 1 mM CaCl2, 0.1 mM PMSF, 2 µg/ml Leupeptin
and 2 µg/ml Aprotinin) and the DNA concentration was measured at 260 nm.
Native chromatin was obtained by mild digestion with micrococcal nuclease (10 units of
enzyme/0.5 mg chromatin) for 10 min at 37°C, and reaction was stopped by addition of
EDTA (20 mM final concentration).
After pelleting by centrifugation at 13414g (13000 rpm) for 5 min at 4°C, the soluble
chromatin was recovered from the supernatant and DNA concentration was measured at
260 nm. On average, up to 30–40% of the starting material was recovered as soluble
chromatin.
DNA was obtained by digestion of extracted native chromatin with 0.5 mg/ml Proteinase K
for 3 h at 45°C. At the end of digestion, DNA was purified by QIAquick PCR purification
kit (Qiagen).
Histone purification
About 5 × 107 HL-60 cells were harvested, washed twice with ice-cold 1X PBS, and
resuspended in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X-100 (v/v), 2
mM PMSF, 0.02% (w/v) NaN3) at a cell density of 107 cells per ml. Cells were lysed on
ice for 10 min with gentle stirring and successively centrifuged at 755g (2000 rpm) for 10
min at 4°C. Pelleted cells were resuspended in 0.2 M HCl at a cell density of 4 × 107 cells
per ml and incubated over night at 4°C in slow rotation. Sample was centrifuged at 755g
for 10 min at 4°C and histones containing supernatant was saved.
38
SDS/KCl Precipitation Assay
Native chromatin, DNA alone and DNA in combination with histones or bovine serum
albumin (BSA) were incubated for 4 h with 4 mM maltonis or formaldehyde (as positive
control) in 100 mM Tris-HCl pH 7.4. Different samples were then diluted in 2.5% SDS/1X
PBS and mixed accurately. KCl was added at the final concentration of 175 mM and
samples were incubated on ice for 5 min. Precipitated proteins and DNA-proteins
complexes were pelleted by centrifugation at 17860g (15000 rpm) for 5 min at 4 °C, and
supernatants, containing the unbound fractions of DNA, were collected. Pellets were
washed two times in ice-cold 0.1 M KCl, 0.1 mM EDTA, 10 mM Tris-HCl pH 7.4; each
wash step was followed by 5 min of incubation on ice and centrifugation at 17860g for 5
min at 4 °C. Supernatants obtained from each wash step were pooled with previous
unbound DNA fractions. Pellets were then resuspended in 1 mL of 0.1 M KCl, 10 mM
EDTA, and 40 mM Tris-HCl pH 6.5 and digested with 0.5 mg/mL proteinase K for 3 h at
45°C. After a further incubation on ice for 5 min, samples were centrifuged at 17860g for 5
min at 4°C and supernatants containing the bound fraction of DNA were collected. Finally,
DNA contents of both bound and unbound fractions were fluorimetrically quantified by
Qubit (Invitrogen).
DNA Electrophoretic Mobility Assay
Native chromatin was incubated for 4 h at 37°C with 4 mM maltonis in 100 mM Tris-HCl
pH 7.4. SDS 0.1% was successively added to separate DNA from histone proteins. DNA
was then analysed by 1.3% agarose gel electrophoresis and detected by ethidium bromide
staining.
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γH2AX immunofluorescence
After 24 hours of treatment with two different concentrations of maltonis (2.5 and 5.0 µM),
HL-60 cells were cytospinned and fixed with 3.7% (v/v) formaldehyde (FA) for 5 min at
RT, followed by two washes with PBS. Fixed cells were treated with 0.1% (v/v) Triton X-
100 in 1X PBS/1% FBS for 10 min at RT. After 30 min of incubation at RT in FBS to
prevent non-specific binding, anti-phospho-H2AX antibody (Alexa Fluor® 488 Conjugate,
#9719, Cell Signaling Technology) was incubated for 1 h at RT in 1X PBS/1% FBS. Cells
were then washed twice with PBS and counterstained with DAPI (diluted 1:3000) for 5
min at RT. Coverslips were then mounted on slides and images were acquired with
Olympus BX50 microscope (Olympus).
Maltonis treated HL-60 cells microarray
HL-60 cells were treated with 5 µM Maltonis for 24 h or left untreated in a duplicate
experiment. After treatment, cells were harvested, washed twice with ice-cold PBS and
resuspended in 0.2 ml of TRIzol (Invitrogen). One hundred nanograms of total RNA were
subjected to 2 cycles of cDNA synthesis with the Affymetrix WT PLUS expression kit. In
the first cycle, first strand synthesis was performed using an engineered set of random
primers that exclude rRNA-matching sequences and include the T7 promoter sequences.
After second strand synthesis, the resulting cDNA was in vitro transcribed with the T7
RNA polymerase to generate a cRNA. This cRNA was subjected to a second cycle of first
strand synthesis in the presence of dUTP in a fixed ratio relative to dTTP. Single strand
cDNA was then purified and fragmented with a mixture of uracil DNA glycosylase and
apurinic/apirimidinic endonuclease 1 (Affymetrix) in correspondence of incorporated
dUTPs. DNA fragments were then terminally labelled by terminal deoxynucleotidyl
transferase (Affymetrix) with biotin. The biotinylated DNA was hybridized to the Human
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GeneChip® HTA 2.0 Array (Affymetrix), containing more than 285000 full length
transcripts covering 44699 coding genes and 22829 non coding genes selected from H.
sapiens genome database RefSeq, ENSEMBL and GenBank. Finally, chips were washed
and scanned on the Affymetrix Complete GeneChip® Instrument System, generating
digitized image data (DAT) files.
Bioinformatics analysis
Microarray analysis was performed exploiting Affymetrix Expression ConsoleTM and
Transcriptome Analysis Console software. Bioinformatics analyses were carried out
through Galaxy platform (https://usegalaxy.org). Galaxy is an open, web-based platform
for biological data analysis and includes interval manipulation utilities for doing set
theoretic operations on intervals (e.g. intersection, union, etc.). Gene ontology analysis was
performed using DAVID Bioinformatics Resource 6.8 (https://david.ncifcrf.gov).
Western blotting
Maltonis treated HL-60 cells were lysed in 1X Sample Buffer (62.5 mM Tris-HCl pH 6.8,
2% SDS, 0.003% bromophenol blue, 10% glycerol, 5% β-mercaptoethanol) at a cell
density of 107 cells per ml. Fifteen microlitres of total lysates were then resolved on a 15%
SDS polyacrylamide gel electrophoresis and immunoblotted with the following specific
antibodies: anti-phospho-H2AX (#07-164, Millipore), anti-H2AX (#07-627, Millipore),
anti-H3K9me3 (#39161, Active Motif), anti-H3 (#06-755, Upstate), anti-HP1α (#Ab9057,
Abcam) and anti-αTubulin (#T9026, Sigma). Secondary goat anti-rabbit IgG, horseradish
peroxidase conjugate (#G21234) and goat anti-mouse IgG, horseradish peroxidase
conjugate (#G21040) were purchased from Thermo Fisher Scientific. Elaboration of
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images and densitometric analysis were performed using ImageJ software (ImageJ 1.43u;
National Institutes of Health).
In vivo evaluation of maltonis efficacy
To evaluate anti-tumour efficacy, non-obese diabetic (NOD)/LtSz-severe combined
immunodeficiency (SCID) IL2Rγnull (NSG) mice were purchased from Charles River,
Italy. Eight weeks old mice were injected intravenously (iv) with 2 × 107 HL-60 cells per
mouse to obtain tumour xenografts. Two days after cells inoculation mice were
randomized in three groups: i) control (n = 4), ii) 5 mg/kg maltonis (n = 4) and iii) 20
mg/kg maltonis (n = 4). Treated group mice received maltonis daily intra-peritoneally (ip)
for 5 days per week, while control group mice were treated with vehicle alone (PBS).
Animal experiments were performed according to European directive 2010/63/UE and
Italian law 26/2014. Experimental protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of the European Institute of Oncology, and
forwarded to the Italian Ministry of Health.
Ki-67 evaluation
Detection of Ki-67 was performed on sections pre-treated with a citrate buffer solution
(0.01 M citric acid and 0.01 M sodium citrate pH 6.0) in a microwave oven at 750 W and
stained with the anti-human Ki67 antibody (Clone MIB-1, #M7240, Dako).
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1. Evaluation of maltonis anti-proliferative effects
A preliminary cancer drug screening, conducted on several maltol-derived compounds
containing a cyclic aliphatic spacer, allowed us to select maltonis (4,10-bis[(3-hydroxy-4-
pyron-2-yl)methyl]-1,7-dimethyl-1,4,7,10-tetraazacyclododecane) for further biological
investigations.
1.1 NCI-60 human tumour cell line anti-cancer drug screen
Maltonis was submitted to National Cancer Institute (NCI) USA, for the NCI-60 human
tumour cell lines screening in order to assess anti-proliferative effect and potential
specificity of the compound. The screen was implemented in fully operational form in
1990 in order to identify and characterize novel compounds able to inhibit or kill tumour
cells. The screen consists of 60 different human tumour cell lines, representing leukaemia,
melanoma, lung, colon, brain, ovarian, breast, prostate, and kidney cancers (Monks, 1991).
In the one dose (10 µM) NCI-60 screening, maltonis showed potent anticancer activity
towards several cancer cell lines of different origin with a global growth inhibition (GI)
value of 46.29% (Figure 1).
Moreover, a deeper characterization of NCI-60 results allowed us to find a significant
inverse correlation between maltonis growth inhibitory effect and cell lines doubling time
with a Pearson’s correlation coefficient of -0.53 and a p-value less than 10-4 (Figure 2).
In light of the data obtained by single dose NCI-60 screening, we focused our research on
haematological malignancies as leukaemia cell lines proved to be among the most sensitive
to maltonis treatments with an average GI value of 58.88% (± 9.91%).
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Figure 1. Maltonis inhibited growth of various cancer cell lines. Maltonis was screened exploiting the
Developmental Therapeutics Program (DTP) from the National Cancer Institute (NCI/NIH). Maltonis was
incubated for 48 hours with 58 different cancer cell lines at a concentration of 10 μM, and percentage cell
growth was measured and compared to untreated samples. Analyses were done as described at
http://dtp.cancer.gov/discovery_development/nci-60.
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Figure 2. Maltonis growth inhibition is dependent on cell lines doubling time. The graph shows the
inverse correlation between maltonis inhibitory effect and cancer cell lines doubling time. Each symbol
represents a cell line in the NCI-60 panel. Pearson’s correlation coefficient = −0.53, p-value ˂ 10-4.
1.2 Characterization of maltonis response in haematopoietic cell lines
In order to further characterize the response of hematopoietic cells to maltonis treatment,
U937, NB-4, JURKAT and HL-60 cell lines were subjected to 72 hours of exposure in
dose-response experiments.
We found that treatments with maltonis at concentrations ranging from 0.5 to 5.0 µM
result in a dose-dependent reduction in cell survival (Figure 3). The IC50 value was
calculated for each cell line showing no appreciable variations among the lines tested with
an average IC50 value of 1.53 ± 0.37 µM.
In addition, as already reported (Guerzoni et al, 2014), two human bone marrow derived
mesenchymal stem cells were used to assess the effects of maltonis on normal cell growth.
Interestingly, human mesenchymal stem cells appeared to be unaffected by the compound
with an IC50 value higher than 50 µM.
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Figure 3. Dose-response experiments on U937, JURKAT, NB-4 and HL-60 tumour cell lines. Reduction
of cell survival induced by maltonis treatments in four haematopoietic tumour cell lines. Cells were treated
for 72 hours with the reported concentrations of maltonis and analysed by Trypan blue dye exclusion assay.
The data are reported as mean ± standard deviation (SD) resulting from three independent experiments.
The biological response to maltonis was further detailed by analysing the effects on cell
cycle progression. Maltonis treatments of 72 hours at concentrations of 0.5, 1.0 and 2.5 µM
induced cell cycle perturbations that were monitored in all the cell lines considered in this
study. The effect was dose-dependent and was characterised by the accumulation of cells
mainly in G2-M phase (Figure 4 and Table 1).
In order to investigate the effects mediated by maltonis, programmed cell death was
evaluated after 72 hours of treatment monitoring the hypodiploid cells percentage. A clear
increase in such percentage was observed at 5.0 µM of maltonis concentration and no
significant differences were noticed between the cell lines tested (Figure 5A).
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Figure 4. Cell cycle alterations induced by maltonis treatments. Cells were exposed for 72 hours to the
reported concentrations of maltonis or left untreated. Cell cycle profiles have been evaluated by flow
cytometric analysis of propidium iodide-stained cells. NT, Not treated.
The activation of the apoptotic programme was subsequently confirmed by analysing the
internucleosomal DNA fragmentation induced by maltonis exposure in HL-60 cells, at
concentrations of 2.5 and 5.0 µM (Figure 5B).
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Table 1. Cell cycle modifications induced by maltonis treatments. Data represent mean values ± standard
deviation of three independent experiments. *Statistically relevant variations respect to untreated controls
(Student’s t test, P < 0.05).
Figure 5. Maltonis-mediated induction of programmed cell death. (A) Percentage of hypodiploid cells
induced by 72 hours of maltonis treatment at the final concentration of 5.0 µM. Hypodiploidy was evaluated
by flow cytometric analysis of propidium iodide stained cells. The data are reported as mean ± SD resulting
from three independent experiments. (B) Apoptosis-related DNA fragmentation induced by 72 hours
maltonis exposure in HL-60 cells at the final concentration of 2.5 and 5.0 µM. NT, Not treated; MK, Marker.
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In light of the in vitro results, that showed comparable IC50 values among the four lines
tested, and considering datasets available in literature, we decided to choose HL-60 cells as
representative experimental model for the following experiments.
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2. Study of maltonis mechanism of action
Previous studies on malten, another maltol-derived compound, revealed its ability to
induce complex structural alterations of genomic DNA due to the generation of DNA inter-
molecular cross-linking (Amatori et al, 2010).
Thus, we investigated the potentiality of maltonis to interfere with chromatin structure so
as to understand whether the formation of covalent bonds could mediate the effect
monitored on the different cell lines.
2.1 Analysis of chromatin structural modifications induced by maltonis
To analyse the hypothesised action of maltonis, we exploited two different cell-free assays:
SDS/KCl precipitation and agarose gel electrophoresis.
Native chromatin, DNA alone and DNA in combination with histones or bovine serum
albumin (BSA) were incubated for 4 hours with 4 mM maltonis and then fractionated by
SDS/KCl precipitation as described in the Materials and methods section. Formaldehyde
(FA) treatment was used as positive control of crosslinking as FA is known to induce
cross-linking of primary amino groups in proteins with other nearby nitrogen atoms in
protein or DNA through a -CH2- linkage (Solomon and Varshavsky, 1985).
A significant increase of DNA in protein-bound fractions was observed both in native
chromatin and DNA plus histone samples treated with maltonis while no increases were
observed when maltonis was added in DNA alone or DNA plus BSA samples (Figure 6A).
These results suggest that in order to perform covalent bonds, maltonis could require DNA
and proteins spatial proximity, as exemplified by native chromatin structure and to a less
extent achievable, through electrostatic interactions, in DNA plus histones samples.
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The DNA-protein binding activity of maltonis was then further investigated on native
chromatin through a canonical agarose gel electrophoretic assay. We showed that, despite
SDS incubation, maltonis treatment was able to impair electrophoretic migration of DNA
whereas no alteration was visible in untreated sample run (Figure 6B).
Figure 6. DNA-protein binding activity of maltonis. (A) SDS/KCl precipitation assay. Native chromatin,
DNA alone and DNA in combination with histones or BSA were treated for 4 hours with 4 mM maltonis or
formaldehyde (as positive control) and then fractioned by SDS/KCl precipitation. The amount of DNA in
protein-bound fractions was fluorimetrically quantified. *P < 0.05, **P < 0.01 respect to untreated samples by
Student’s t test. (B) Impaired electrophoretic mobility of chromatin. Native chromatin was treated for 4 hours
with 4 mM maltonis, incubated or not in 0.1% SDS solution and separated by agarose gel electrophoresis.
SDS, Sodium dodecyl sulfate; NT, Not treated; m, Maltonis.
Taken together, these observations demonstrate that maltonis is able to induce covalent
protein-DNA binding, thus altering chromatin structure.
2.2 Evaluation of DNA damages induced by maltonis
In light of the cell-free assay results, we hypothesised that covalent cross-links induced by
maltonis treatments could underlie the formation of DNA double-strand breaks and
activate DNA-damage response (DDR).
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Therefore, we assessed, by an immunofluorescence approach, the phosphorylation of
histone H2AX (γH2AX) as marker of DDR on HL-60 cells. We detected an increase of
γH2AX marker at 24 hours of treatment with two different concentrations of maltonis (2.5
and 5.0 µM) (Figure 7A).
We confirmed this result by performing a western blot analysis of phosphorylated H2AX
histone. A dose-dependent increase was monitored in HL-60 cells treated for 24 hours with
maltonis (+6.74 fold at 2.5 µM and +8.19 fold at 5.0 µM of maltonis respect to untreated
control, Figure 7B).
Figure 7. Maltonis treatment induces DNA damage response activation. (A) Induction of H2AX
phosphorylation (γH2AX) in HL-60 cells after exposure for 24 hours to 2.5 and 5.0 μM maltonis
(magnification × 40). (B) Western blot analysis of cell lysates obtained from maltonis-treated and untreated
HL-60 cells. DAPI, 4',6-Diamidino-2-phenylindole dihydrochloride; NT, Not treated.
2.3 Gene expression profile of maltonis-treated HL-60 cells
To better define the molecular response triggered by maltonis, we evaluated gene
expression profile of maltonis-treated HL-60 cells by a microarray analysis using an
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untreated sample as reference.
We carried out the experiment in duplicate exposing HL-60 cells to 5.0 µM maltonis for a
short-time (24 hours), so as to avoid apoptotic programme activation.
DNA microarray is a high-throughput technique that permits the analysis of several
thousands of genes in one single experiment, providing a snapshot of the gene expression
profile resulting from a drug treatment (Cheung et al, 1999; Duggan et al, 1999).
In our experiments, we used the GeneChip® Human Transcriptome Array 2.0, which
allows the differential expression analysis of 67528 transcript clusters, 44699 coding and
22829 non-coding regions. To normalize, perform data quality control, and summarize data
from tens of thousands of genes, we exploited the Affymetrix Expression ConsoleTM
software.
The Principle Component Analysis (PCA) as well as the Pearson’s correlation plot showed
a clear distinction between the maltonis-treated and the untreated samples (Figure 8), thus
giving a first hint regarding the capability to distinguish different features in maltonis-
treated HL-60 cells.
Figure 8. Principal component analysis and Pearson’s correlation graph. (A) PCA plot was performed
using normalized data obtained by DNA microarray analysis of maltonis-treated (green squares) and
untreated (red squares) HL-60 cells. Principal components 1 (PC1) and PC2 values are reported in graph. (B)
Pearson’s correlation matrix of normalized DNA microarray data.
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To perform further analysis of the data, we used the Transcriptome Analysis Console
(TAC) software by Affymetrix so as to obtain a list of differentially expressed genes. We
used the unpaired one-way between-subject ANOVA algorithm applying two filter criteria:
a fold change threshold equal to 2 and an ANOVA p-value lower than 0.05.
Setting these parameters, we selected 3491 genes differentially expressed in maltonis
treated HL-60 cells respect to the untreated controls. Out of 3491 genes, 2503 were up-
regulated by maltonis treatment while 988 were down-regulated (Figure 9).
Figure 9. Scatter plot. Scatter plot depicts the expression levels (calculated as log2) in maltonis-treated and
untreated HL-60 cells. Genes whose expression levels are identical in the two conditions are located on the
bisector. Green crosses represent transcripts up-regulated following maltonis treatment, whereas red crosses
symbolize the ones down-regulated. Genes showing a regulation exceeding the 2-fold criterion and an
ANOVA p-value ˂ 0.05 were considered as differentially expressed. NT, Not treated.
We then used the Database for Annotation, Visualization and Integrated Discovery
(DAVID) analytic tools to identify enriched biological themes by Gene Ontology (GO)
analysis (Huang et al, 2009).
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Differentially expressed genes selected by filter criteria were analysed and the main gene
ontology categories involved in maltonis response are showed in figure 10.
Figure 10. Gene ontology (GO) analysis of regulated genes in maltonis-treated HL-60 cells. GO analysis
was performed using the ‘Functional Annotation Tool’ in DAVID (http://david.ncifcrf.gov/) and biological
process terms are indicated. Pathways with a p-value greater than 0.05 were filtered out. The top 10 pathways
are shown for the up-regulated genes, while, for the down-regulated genes, the only process that matched the
p-value criterion is plotted.
In agreement with previous data, the expression of genes involved in cell division and
DNA repair was affected in response to maltonis treatment. The analysis revealed the up-
regulation of several cyclin and cyclin-dependent kinase genes (e.g. CCNT1, CCNL1,
CCNH, CDK6, CDK12, etc.). Likewise, ATM (Ataxia telangiectasia mutated), ATR
(Ataxia telangiectasia and Rad3 related) and many other genes implicated in DDR
activation was considerably up-regulated.
Strikingly, mRNA processing, splicing and export from nucleus were among the most
enriched pathways, suggesting a strong maltonis-mediated effect on RNA regulation.
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In addition, genes involved in DNA unwinding process were up-regulated in maltonis
treated HL-60 cells, thus supporting the hypothesis that maltonis induced crosslinking
could play a role in the anti-proliferative effect observed in in vitro experiments.
Conversely, the negative regulation of transcription from RNA polymerase II promoter
was the only gene ontology category enriched among the down-regulated genes.
Furthermore, a deep analysis of the chromosome summary graph, obtained by TAC
software, allowed us to identify the accumulation of down-regulated (DR) genes in specific
chromosomes in a percentage higher than the random expected distribution dependent by
the size of chromosomes (Figure 11).
Figure 11. Chromosome summary of down-regulated genes in maltonis-treated HL-60 cells. Map of
down-regulated transcript positions along chromosomes (black square). The size of each chromosome
summary square represents its gene size. In some instances, a square appears larger because it may contain
multiple probe sets due to minimal pixel limitation. Chromosomes 16, 17, 19 and 22 are distinctly enriched
in down-regulated transcripts.
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2.4 Analysis of down-regulated genes distribution
Remarkably, as stated above, the distribution of DR genes upon maltonis treatments was
partially related to specific regions of chromosomes and the majority of DR genes were not
functionally regulated.
A bioinformatics analysis showed a strong correlation between DR genes and GC-rich
regions. As shown in Figure 12, GC percentage was higher in body of DR genes compared
to reference standard (RefSeq) genes (55.34% and 41.97%, respectively). In addition, we
calculated the GC percentage also in up-regulated (UR) genes, showing in this case a
comparable value respect to RefSeq genes. The same analysis was repeated evaluating
GC% profile around the transcription start site (TSS ± 2.5 kb) of genes. Again, we
monitored the same trend previously observed for gene bodies (Figure 12).
Figure 12. Maltonis treatment induces down-regulation of GC-rich genes. The histogram depicts GC
percentage over the indicated regions. Both gene bodies and transcription start sites of down-regulated genes
(indicated as DR and TSS DR, respectively) are enriched in GC content respect either to RefSeq or up-
regulated genes (UR). CpG islands (CGIs) were considered as GC-rich regions. RefSeq defines genomic
sequences to be used as reference standards for well-characterized genes.
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The attractive hypothesis that maltonis could function interacting with specific features of
chromatin structure was further investigated by analysing the correlation of DR genes with
genome sequences prone to adopt G-quadruplex DNA structures. By comparing our data
with that obtained by Rodriguez et al (2012), we calculated the percentage of DR genes
that contained a putative-quadruplex sequences (PQSs) percentage higher than the whole-
transcriptome median value 0.257%. PQS% represents the percentage of bases of a gene
that are located within the PQSs mapped by the Quadparser algorithm (Huppert and
Balasubramanian, 2005). As shown in figure 13, about 87% of DR genes contain a PQS%
higher than the median value, while only 15% of UR genes fall into the same group.
Figure 13. Down-regulated genes mainly lie within putative G-quadruplex regions. Pie charts show the
percentages of down- and up-regulated genes (DR and UR, respectively) that lie within putative G-
quadruplex sequences (PQSs). The majority of DR genes fall into genomic regions that have a PQS
percentage higher than the median value (PQS% high) whereas just a small percentage of UR genes fall into
the same group.
Overall, these results suggest a potential affinity of maltonis towards GC-rich regions with
a particular propensity to recognize G-quadruplex structures.
Recent evidence showed that G-quadruplex sequence motifs are prevalent in the human
genome and are enriched in gene regulatory regions and gene bodies, and in repetitive
sequences, such as telomeres (Todd et al, 2005; Verma et al, 2008).
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Thus, we tried to evaluate whether the affinity of maltonis towards G-quadruplex
structures could influence specific features of telomeres.
In particular, we focused on the trimethylation at lysine 9 of histone H3 (H3K9me3) and
on the related Heterochromatin protein 1 alpha (HP1α, also called CBX5).
H3K9me3 mark and HP1 proteins are commonly found in constitutive heterochromatin
and are enriched at telomeres where they may contribute to further compaction of
telomeric and subtelomeric regions (Majocchi et al, 2014).
We carried out a western blot analysis on HL-60 cell lysates, following a 24 hours
treatment with 2.5 and 5.0 µM of maltonis (Figure 14). Interestingly, we noticed a
decrease, at 5.0 µM of maltonis treatment, in the signal of both H3K9me3 mark and HP1α
protein (−3.41 fold and −1.91 fold respect to untreated control, respectively).
Figure 14. Maltonis treatment reduces HP1α protein levels and inhibits H3K9 trimethylation. Western
blot analysis of cell lysates obtained from maltonis-treated and untreated HL-60 cells. NT, Not treated.
These results support the hypothesis of a potential interference on telomeric structures
related to covalent bonds induced by maltonis.
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3. In vivo evaluation of maltonis efficacy
In a first pilot experiment, we evaluated the therapeutic potential and toxicity of maltonis
in a human AML (HL-60) xenograft murine model.
Non-obese diabetic (NOD)/LtSz-severe combined immunodeficiency (SCID) IL2Rγnull
(NSG) mice were intravenous inoculated with 2 × 107 HL-60 cells to mimic the
invasiveness and proliferative capacity of primary AML, leading to the disseminated
growth of tumour cells and ultimately to death within 4-5 weeks (Agliano et al, 2008).
Two days after cell injection, mice were divided into three subgroups (n=4, for each
group): control mice were treated with vehicle alone (phosphate buffered saline, PBS),
whereas treated mice received injection of maltonis, at two different concentrations (5
mg/kg and 20 mg/kg), once a day for 5 days per week. Intraperitoneal (ip) drug
administration was chosen as first attempt in order to administer large volumes of fluid
simply and safely. At the indicated doses, maltonis was very well tolerated: we did not
observe any significant changes in mice weight, blood glucose and urea levels or other
signs of collateral toxicity. Preliminary results showed a slight but significant (p-value less
than 0.05) increase in the overall survival time of mice treated with 20 mg/kg of maltonis
while no significant differences were observed in the group treated with 5 mg/kg of
maltonis. In particular, the mean survival time for control mice was 34.7 (± 0.5) days,
while the mean survival times in treated groups were estimated to be 35.7 (± 1.2) days and
37.5 (± 0.6) days for 5 mg/kg and 20 mg/kg of maltonis, respectively.
Moreover, as HL-60 cells generated abdominal solid tumours, we evaluated the
proliferation marker Ki67 expression in histological tissues of control and treated mice,
showing Ki67 inhibition at high concentrations of maltonis (Figure 15).
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Figure 15. Maltonis anti-proliferative effect in human AML (HL-60) xenograft murine model.
Representative immunohistochemical evaluation of Ki67 in control and maltonis-treated tumour
(magnification × 200).
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DISCUSSION
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Despite increasing advances in modern treatments for tumours, the survival of many
patients affected by cancer remains extremely poor. The high possibility of relapse, the
absence of specific therapies and resistance to standard chemotherapy represent the main
causes of failure in cancer treatment (Tobias and Hochhauser, 2010). Thus, there is an
urgent necessity for research focused on the identification and description of new anti-
tumour agents.
In this study, we provide the biological properties of a new synthetic maltol-derived
molecule, maltonis, and the preliminary attempts to understand its molecular mechanism of
action.
The sensitivity to maltonis exposure of several tumour cell lines of different origin was
assayed through NCI-60 human tumour cell lines screen, highlighting a correlation
between maltonis biological effect and cell lines doubling time. Subsequently, focusing on
haematopoietic cell lines (U937, HL-60, NB-4 and JURKAT), we showed that maltonis is
able to drastically reduce the cell survival of the four cell lines tested, and to induce
programmed cell death and cell cycle perturbations. High doses of maltonis activated the
apoptotic cellular response, whereas sublethal treatments induced the accumulation of cells
mainly in G2-M phase.
The late S and G2-M block is usually associated with compounds known to form adducts
with DNA and currently included in several therapeutic protocols (Siddik, 2003). As a
consequence of these observations, the possible DNA structural alterations induced by
maltonis have been investigated by cell-free studies. We showed that maltonis exposure
induces the formation of covalent bonds at the chromatin level strongly impairing DNA
electrophoretic mobility.
Interestingly, a similar interference has been already described for some DNA alkylating
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compounds (Pereira et al, 1998; David-Cordonnier et al, 2002; Novakova et al, 2009) and
it has been associated with the formation of a DNA matrix of high molecular weight,
which results from the inter-helical crosslinking of multiple DNA molecules.
In light of these results, we investigated whether maltonis physical interaction with the
chromatin structure was sufficient to alter nucleic acid properties and recruit the DNA
repair system. Formation of γH2AX nuclear foci was observed in HL-60 cells following a
short treatment with maltonis, revealing the recruitment of DNA damage response (DDR)
machinery likely due to cross-linking induced DNA double strand breaks (DSBs). DDR
activation was also confirmed by microarray-based comparative gene expression analysis
of maltonis treated HL-60 cells, that showed an up-regulation of DNA repair genes.
Moreover, in accordance with the observed cell cycle perturbations, gene ontology (GO)
analysis revealed cell division as a major pathway regulated by maltonis treatment.
Likewise, genes involved in RNA processing, DNA synthesis and DNA replication were in
the top ten GO categories of maltonis regulated genes, further supporting the hypothesis of
a possible interference closely related to the maltonis ability to interact with nucleic acids.
Maltonis-mediated regulation of DNA replication genes is in agreement with the
correlation found in the previous analysis of NCI-60 screening between maltonis growth
inhibitory effect and cell lines doubling time.
Conversely, GO analysis of genes down-regulated by maltonis treatment highlighted the
negative regulation of transcription from RNA polymerase II promoter as the only
significant GO category. Furthermore, down-regulated genes genome-wide distribution
was proved to be dependent on GC-rich regions and G-quadruplex structures.
Taken together, these results suggest that the negative regulation of genes observed in
microarray analysis could be related, at least partially, to maltonis-mediated crosslinking at
the chromatin level.
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In addition, recent evidence demonstrated that GC content and genomic distribution of G-
quadruplex motifs are highly correlated with telomeric regions and replication origin
locations (Besnard et al, 2012; Cayrou et al, 2012; Rhodes and Lipps, 2015). In particular,
Besnard and co-authors propose a model in which the specific distribution of G4 motifs in
the human genome is involved in both origin selection and efficiency, constituting a
driving force for establishment of the spatiotemporal programme of replication.
Therefore, the possibility that maltonis interaction with GC-rich sequences and G-
quadruplex structures might affect DNA replication and/or telomere maintenance could
represent an intriguing mechanistic hypothesis, worthy to be further investigated.
The in vitro efficacy of maltonis was also tested in vivo on a human AML (HL-60)
xenograft murine model. In a preliminary experiment, treatments with maltonis at the
concentration of 20 mg/kg produced a significant increase in the survival time of xenograft
mice. Cell proliferation inhibition was observed, thus substantially confirming results
obtained in vitro.
Current experiments aim to better define the sites of maltonis interaction, by γH2AX
chromatin immunoprecipitation followed by high throughput sequencing (ChIP-seq), and
to further evaluate in vivo maltonis anti-cancer potential.
Overall, although additional investigations will be necessary, results obtained in this study
suggest a potential role for maltonis as anti-cancer agent.
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